Ibere Pharmaceuticals Announces the Separate Trading of its Class A Ordinary Shares and Redeemable Warrants Commencing April 19, 2021

Rhea-AI Summary

Ibere Pharmaceuticals announced the commencement of separate trading for its Class A ordinary shares and redeemable warrants from April 19, 2021. This follows the completion of their initial public offering on March 2, 2021, where they sold 13,800,000 units at $10.00 each, raising $138 million. The units will continue to trade under the symbol 'IBERU', while the Class A shares and warrants will trade under 'IBER' and 'IBERW', respectively. No fractional warrants will be issued upon separation, and holders must contact their brokers to separate the units.

Positive

• Raised $138 million from initial public offering.
• Units began separate trading, providing liquidity options for investors.

Negative

• None.

PHILADELPHIA, April 19, 2021 /PRNewswire/ -- Ibere Pharmaceuticals (the "Company") today announced that, commencing April 19, 2021, holders of the units sold in the Company's initial public offering of 13,800,000 units at $10.00 per unit, completed on March 2, 2021, may elect to separately trade the Class A ordinary shares and redeemable warrants included in the units. Those units not separated will continue to trade on the New York Stock Exchange (the "NYSE") under the symbol "IBERU" and the Class A ordinary shares and redeemable warrants that are separated will trade on the NYSE under the symbols ""IBER" and "IBERW" respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Co., the Company's transfer agent, in order to separate the units into Class A ordinary shares and redeemable warrants.

Founded by long-time pharmaceutical and healthcare industry veteran executives Osagie O. Imasogie, Lisa Gray and Zoltan Kerekes, Ibere Pharmaceuticals is a special purpose acquisition company newly formed to acquire, manage and grow strong, international brand portfolios that scale across markets globally. The Company intends to focus on opportunities in the pharmaceutical and life sciences industries. The Company's principals have built transformational growth companies by leveraging deep industry relationships developed using their PATCOL^® philosophy (People Are The Currency Of Life) and by applying their extensive knowledge of pharmaceutical operations.

Raymond James & Associates, Inc. acted as the sole book-running manager for the offering. Registration statements relating to the units and the underlying securities were declared effective by the Securities and Exchange Commission (the "SEC") on February 25, 2021.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, Florida 33716, Attention: Equity Syndicate, 1-800-248-8863, prospectus@raymondjames.com.

About Ibere Pharmaceuticals

Ibere Pharmaceuticals is a newly formed special purpose acquisition company that completed its initial public offering in March 2021, raising $138 million in proceeds. Led by Osagie O. Imasogie, Lisa Gray and Zoltan Kerekes, Ibere Pharmaceuticals was formed to acquire, manage and grow strong, international brand portfolios that scale across markets globally. The Firm's principals have built transformational growth companies by leveraging deep industry relationships developed using their PATCOL^® philosophy (People Are The Currency Of Life) and by applying their extensive knowledge of pharmaceutical operations.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Media Contacts
Jonathan Keehner / Kate Thompson / Tanner Kaufman
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

View original content:http://www.prnewswire.com/news-releases/ibere-pharmaceuticals-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-redeemable-warrants-commencing-april-19-2021-301271443.html

SOURCE Ibere Pharmaceuticals

FAQ

When did Ibere Pharmaceuticals commence separate trading of its Class A shares and warrants?

Ibere Pharmaceuticals commenced separate trading of its Class A ordinary shares and redeemable warrants on April 19, 2021.

What is the significance of Ibere Pharmaceuticals' initial public offering?

Ibere Pharmaceuticals raised $138 million through its initial public offering completed on March 2, 2021.

What symbols do Ibere Pharmaceuticals' securities trade under?

Ibere Pharmaceuticals' units trade under 'IBERU', Class A shares under 'IBER', and redeemable warrants under 'IBERW'.

How can holders separate their units of Ibere Pharmaceuticals?

Holders of units need to contact their brokers to separate the units into Class A ordinary shares and redeemable warrants.